AI Accelerates Drug Discovery: How giles® is Transforming Healthcare Research

The pharmaceutical industry faces a significant bottleneck: the time-consuming process of literature review. Bringing a modern drug to market typically takes 10 to 12 years, with roughly a third of that time dedicated to research [1]. Researchers must sift through an ever-growing volume of scientific publications – PubMed currently hosts over 39 million citations [1] – to identify crucial insights for clinical trials and regulatory submissions. This protracted process delays access to potentially life-saving treatments.

The Rise of AI-Powered Research Assistants

AI research assistant giles® aims to address this challenge by dramatically reducing the time and cost associated with drug development, ultimately accelerating the delivery of new therapies. Designed to emulate the thought processes of healthcare professionals, giles® swiftly extracts and summarizes key data from extensive literature, expediting the discovery process.

Addressing the Trust Gap in AI for Healthcare

Trust is paramount in healthcare. Inaccurate AI outputs can have serious consequences for patients. Recognizing this, giles® was initially developed using third-party AI models but has evolved to overcome the limitations of “hallucinations” – instances where large language models generate incorrect information when lacking a definitive answer. The platform prioritizes consistently accurate data delivery to researchers.

Key Features of giles®

• Comprehensive Search: giles® allows users to search millions of papers from sources like PubMed, the National Institute for Health and Care Excellence (NICE) and the Food and Drug Administration (FDA) [3].
• Efficient Screening: Abstracts are readily viewable within giles®, enabling rapid assessment of relevance. Smart filters further refine search results.
• Comparative Data Analysis: The platform facilitates side-by-side comparison of multiple studies, providing clarity and aiding in informed decision-making.
• Simplified Synopsis: giles® can generate overviews of study methods, results, and conclusions from multiple documents.
• Research Summarization: Long documents are condensed into concise, easily digestible insights.
• Data Extraction: Quantitative and qualitative data can be extracted with up to 94% accuracy [3].
• Source Verification: Users can directly access and review original sources to confirm the accuracy of extracted information [3].
• Organized Research: Dedicated workspaces allow researchers to group and manage their projects efficiently.

Recent Advances Highlighted by PubMed

Recent research showcased on PubMed demonstrates the ongoing advancements in medical science. Studies include investigations into the impact of COVID-19 vaccination on individuals with radiologically isolated syndrome [1], the identification of genetic diversity in Synsepalum dulcificum [1], and the development of mucosal vaccines for respiratory protection [1]. A 2026 baseline release of updated MEDLINE citations with 2026 MeSH is scheduled for the week of January 26, 2026 [1].

Clinical Trial Information Accessibility

Researchers can also leverage resources like ClinicalTrials.gov to access information about ongoing clinical studies [2].

The Future of Drug Development

AI-powered tools like giles® represent a significant step towards streamlining the drug development process. By automating literature review and ensuring data accuracy, these technologies promise to accelerate the delivery of innovative treatments to patients in need. As AI continues to evolve, its role in healthcare research will undoubtedly expand, leading to faster breakthroughs and improved patient outcomes.